BF2.649 + modafinil

BF2.649 + modafinil is an investigational oral combination therapy studied for the treatment of narcolepsy, particularly targeting excessive daytime sleepiness and cataplexy. - **BF2.649** (also known as pitolisant or tiprolisant) is a first-in-class histamine H3 receptor antagonist/inverse agonist that enhances histaminergic neurotransmission in the brain to promote wakefulness and reduce cataplexy[4][5]. - **Modafinil** is a central nervous system stimulant and eugeroic agent that promotes wakefulness by inhibiting dopamine reuptake and activating glutamatergic circuits while inhibiting GABAergic transmission; its precise mechanism remains unclear[6][8][9]. The combination has been evaluated in randomized controlled trials to assess additive or synergistic effects on reducing cataplexy attacks and improving vigilance/attention in patients with narcolepsy[1][5]. The rationale for combining these agents stems from preclinical evidence showing enhanced cortical histamine release and noradrenergic activity when both drugs are administered together compared to either alone[4].

Other names

pitolisant + modafiniltiprolisant + modafinil